رسالة جامعية
Proteomic identification of putative biomarkers of neo-adjuvant chemotherapy resistance in luminal (ER+) breast cancer
| العنوان: | Proteomic identification of putative biomarkers of neo-adjuvant chemotherapy resistance in luminal (ER+) breast cancer |
|---|---|
| المؤلفون: | Hussain, Tasadooq |
| بيانات النشر: | University of Hull, 2013. |
| سنة النشر: | 2013 |
| المجموعة: | Ethos UK |
| Original Material: | http://hydra.hull.ac.uk/resources/hull:7395Test |
| مصطلحات موضوعية: | 610, Medicine |
| الوصف: | Background: Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer however chemoresistance can be a major obstacle in ER+ cancers. Using comparative proteomic approaches (antibody microarray/AbMA and 2D-PAGE with MALDI-TOF/TOF MS) to investigate a pilot series of breast cancer samples our research group recently identified 14-3-3 theta/tau, tBID and BcL-XL as putative biomarkers of response to neoadjuvant chemotherapy (Hodgkinson et al J Prot 2012, 75:1276-1283 and 75:2745-2752). Here we aimed to analyse further samples using the AbMA approach and to re-analyse the combined data. Methods: Samples from chemoresistant and chemosensitive breast cancers were selected following anthracycline-taxane chemotherapy and 4 experiments were performed using ductal ER+ tumours. Differential protein expression was compared between chemoresistant and chemosensitive samples using the Panorama XPRESS Profiler725 AbMA kit. The combined data from 9 AbMA assays and 3 2D-PAGE/MS experiments was then analysed using Ingenuity Pathway Analysis (IPA; Ingenuity Systems). A pilot series of archival samples was used for clinical validation of putative predictive biomarkers. Results: 89 differentially expressed proteins (DEPs) were seen in the 4 further AbMA experiments. In the combined dataset (12 experiments from 2 proteomic platforms), 8 DEPs were seen in at least 3 experiments. These were 14-3-3 theta, 14-3-3 epsilon, 14-3-3 gamma, Bcl-xl, Bid, Phosphokinase B, Vimentin and FAK. 121 DEPs from the combined data were analysed using IPA; 13 DEPs were mapped onto the PI3K/AKT pathway. Clinical validation in a pilot series of archival samples revealed AkT-1 Ser473 and FAKY397 alongside the previously identified and validated 14-3-3 theta/tau, and tBID to be significantly associated with chemotherapy resistance. Conclusion: We have now identified at least 8 proteins which could play a role in breast chemoresistance. We propose a potential role for AkT-1, FAK, 14-3-3 theta/tau and tBID as predictive biomarkers of neoadjuvant chemotherapy resistance in breast cancer. Further validation in a larger sample series is now required. |
| Original Identifier: | oai:ethos.bl.uk:587047 |
| نوع الوثيقة: | Electronic Thesis or Dissertation |
| الإتاحة: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.587047Test |
| رقم الانضمام: | edsndl.bl.uk.oai.ethos.bl.uk.587047 |
| قاعدة البيانات: | Networked Digital Library of Theses & Dissertations |
| ResultId |
1 |
|---|---|
| Header |
edsndl Networked Digital Library of Theses & Dissertations edsndl.bl.uk.oai.ethos.bl.uk.587047 774 3 Dissertation/ Thesis dissertation 773.889099121094 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsndl&AN=edsndl.bl.uk.oai.ethos.bl.uk.587047&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Proteomic identification of putative biomarkers of neo-adjuvant chemotherapy resistance in luminal (ER+) breast cancer
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Hussain%2C+Tasadooq%22">Hussain, Tasadooq</searchLink> ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => University of Hull, 2013. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2013 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Ethos UK ) Array ( [Name] => Original Material [Label] => Original Material [Group] => [Data] => http://hydra.hull.ac.uk/resources/hull:7395 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22610%22">610</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background: Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer however chemoresistance can be a major obstacle in ER+ cancers. Using comparative proteomic approaches (antibody microarray/AbMA and 2D-PAGE with MALDI-TOF/TOF MS) to investigate a pilot series of breast cancer samples our research group recently identified 14-3-3 theta/tau, tBID and BcL-XL as putative biomarkers of response to neoadjuvant chemotherapy (Hodgkinson et al J Prot 2012, 75:1276-1283 and 75:2745-2752). Here we aimed to analyse further samples using the AbMA approach and to re-analyse the combined data. Methods: Samples from chemoresistant and chemosensitive breast cancers were selected following anthracycline-taxane chemotherapy and 4 experiments were performed using ductal ER+ tumours. Differential protein expression was compared between chemoresistant and chemosensitive samples using the Panorama XPRESS Profiler725 AbMA kit. The combined data from 9 AbMA assays and 3 2D-PAGE/MS experiments was then analysed using Ingenuity Pathway Analysis (IPA; Ingenuity Systems). A pilot series of archival samples was used for clinical validation of putative predictive biomarkers. Results: 89 differentially expressed proteins (DEPs) were seen in the 4 further AbMA experiments. In the combined dataset (12 experiments from 2 proteomic platforms), 8 DEPs were seen in at least 3 experiments. These were 14-3-3 theta, 14-3-3 epsilon, 14-3-3 gamma, Bcl-xl, Bid, Phosphokinase B, Vimentin and FAK. 121 DEPs from the combined data were analysed using IPA; 13 DEPs were mapped onto the PI3K/AKT pathway. Clinical validation in a pilot series of archival samples revealed AkT-1 Ser473 and FAKY397 alongside the previously identified and validated 14-3-3 theta/tau, and tBID to be significantly associated with chemotherapy resistance. Conclusion: We have now identified at least 8 proteins which could play a role in breast chemoresistance. We propose a potential role for AkT-1, FAK, 14-3-3 theta/tau and tBID as predictive biomarkers of neoadjuvant chemotherapy resistance in breast cancer. Further validation in a larger sample series is now required. ) Array ( [Name] => AN [Label] => Original Identifier [Group] => ID [Data] => oai:ethos.bl.uk:587047 ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => Electronic Thesis or Dissertation ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.587047 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsndl.bl.uk.oai.ethos.bl.uk.587047 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => 610
[Type] => general
)
[1] => Array
(
[SubjectFull] => Medicine
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Proteomic identification of putative biomarkers of neo-adjuvant chemotherapy resistance in luminal (ER+) breast cancer
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hussain, Tasadooq
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2013
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsndl
)
)
)
)
)
)
)
|
| IllustrationInfo |